サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1762315

GLP-1市場、規模、シェア、産業分析レポート：投与経路別、分子タイプ別、使用活性化合物別、GLP-1作動薬タイプ別、ターゲット適応症別、地域別、2025年～2034年の市場予測

GLP-1 Market Size, Share, & Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 129 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
GLP-1市場、規模、シェア、産業分析レポート：投与経路別、分子タイプ別、使用活性化合物別、GLP-1作動薬タイプ別、ターゲット適応症別、地域別、2025年～2034年の市場予測
出版日: 2025年05月01日
発行: Polaris Market Research
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、GLP-1市場の市場規模は2034年までに1,339億2,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

GLP-1（グルカゴン様ペプチド-1）はインクレチンホルモンの一種で、インスリンの分泌を促し、グルカゴンの分泌を取り込むことによって糖代謝に大きな役割を果たします。治療的には、GLP-1受容体作動薬が2型糖尿病の治療や体重管理のサポートに使用されています。GLP-1受容体作動薬は、2型糖尿病の治療や体重管理のほか、肥満や心血管系リスクなど、より広範な慢性疾患管理の枠組みにも組み込まれつつあります。GLP-1受容体作動薬は、その臨床的有用性がより広く認識されるにつれて、進化する治療ガイドラインに沿ったマルチターゲット薬剤として採用されつつあります。GLP-1受容体作動薬は、その臨床的有用性が広く認識されるにつれて、治療ガイドラインに沿ったマルチターゲット薬として採用されつつあり、このような有用性の拡大により、全体的なアウトカム重視のケアソリューションを求めるヘルスケアプロバイダーや患者の関心が高まっています。

製薬企業が主導する継続的な技術革新は、ドラッグデリバリー、利便性、患者のコンプライアンスを向上させることを目指しています。各社は、より少ない副作用と少ない投与回数で代謝転帰を改善する次世代製剤や併用療法への投資を増やしています。これと並行して、個別化された治療プロトコールへの注目の高まりが、患者のプロファイルに合わせた精密ベースのGLP-1療法の開発を促しています。これらの進歩は総体的に、より個別化された長期的な疾病管理戦略への市場のシフトを示唆しています。

GLP-1市場レポートハイライト

GLP-1アゴニスト医薬品の種類別では、投与間隔の延長、患者のコンプライアンス向上、一貫した臨床転帰などを理由に、長時間作用型GLP-1アゴニストが2024年の市場をリードしました。

投与経路別では、経口GLP-1製剤が予測期間中に最も急成長すると予測されています。

2024年には、北米が最大の売上シェアを占め、糖尿病/肥満率の高さ、最先端のヘルスケアシステム、革新的な治療法の急速な普及に支えられています。

アジア太平洋地域は、生活習慣に関連した代謝性疾患の急増とヘルスケアへのアクセスの拡大により、最も高い成長が見込まれています。

世界の主要市場プレーヤーには、アストラゼネカ、ベーリンガーインゲルハイム、D&Dファーマテック、イーライリリー、ハンミ製薬、ノボノルディスク、ファイザー、ロシュ、サノフィ、東方製薬などがいます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のGLP-1市場の洞察

  • マテリアルスナップショット
  • GLP-1市場力学
    • 促進要因と機会
      • 世界的に2型糖尿病の有病率が上昇
      • 肥満および関連する代謝障害の増加率
    • 抑制要因と課題
      • GLP-1薬の高コストと購入の課題
  • PESTEL分析
  • GLP-1市場の材料動向
  • バリューチェーン分析

第5章 世界のGLP-1市場：分子タイプ別

  • 主な調査結果
  • イントロダクション
  • 生物学的製剤
  • 小分子

第6章 世界のGLP-1市場：使用活性化合物別

  • 主な調査結果
  • イントロダクション
  • デュラグルチド
  • リラグルチド
  • オルフォルグリプロン
  • レタトルチド
  • セマグルチド
  • スルボドゥチド
  • チルゼパチド
  • その他の有効成分

第7章 世界のGLP-1市場：GLP-1作動薬タイプ別

  • 主な調査結果
  • イントロダクション
  • 長時間作用型GLP-1アゴニスト
  • 短時間作用型GLP-1作動薬

第8章 世界のGLP-1市場：投与経路別

  • 主な調査結果
  • イントロダクション
  • 経口
  • 非経口

第9章 世界のGLP-1市場：ターゲット適応症別

  • 主な調査結果
  • イントロダクション
  • アルツハイマー病
  • 非アルコール性脂肪肝炎
  • 肥満
  • 睡眠時無呼吸症候群
  • 2型糖尿病

第10章 世界のGLP-1市場：地域

  • 主な調査結果
  • イントロダクション
    • GLP-1市場評価：地域、2020～2034年
  • 北米
    • 分子タイプ別、2020～2034年
    • 使用活性化合物別、2020～2034年
    • GLP-1作動薬タイプ別、2020年～2034年
    • 投与経路別、2020～2034年
    • ターゲット適応症別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 分子タイプ別、2020～2034年
    • 使用活性化合物別、2020～2034年
    • GLP-1作動薬タイプ別、2020年～2034年
    • 投与経路別、2020～2034年
    • ターゲット適応症別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • 分子タイプ別、2020～2034年
    • 使用活性化合物別、2020～2034年
    • GLP-1作動薬タイプ別、2020年～2034年
    • 投与経路別、2020～2034年
    • ターゲット適応症別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 分子タイプ別、2020～2034年
    • 使用活性化合物別、2020～2034年
    • GLP-1作動薬タイプ別、2020年～2034年
    • 投与経路別、2020～2034年
    • ターゲット適応症別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • 分子タイプ別、2020～2034年
    • 使用活性化合物別、2020～2034年
    • GLP-1作動薬タイプ別、2020年～2034年
    • 投与経路別、2020～2034年
    • ターゲット適応症別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第11章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第12章 企業プロファイル

  • AstraZeneca
  • Boehringer Ingelheim
  • D&D Pharmatech
  • Eli Lilly
  • Hanmi Pharmaceutical
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Tonghua Dongbao Pharmaceutical
図表

List of Tables:

  • Table 1 Global GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 2 Global GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 3 Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 4 Global GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 5 Global GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 6 North America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 7 North America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 8 North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 9 North America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 10 North America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 11 US: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 12 US: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 13 US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 14 US: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 15 US: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 16 Canada: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 17 Canada: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 18 Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 19 Canada: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 20 Canada: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 21 Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 22 Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 23 Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 24 Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 25 Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 26 UK: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 27 UK: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 28 UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 29 UK: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 30 UK: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 31 France: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 32 France: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 33 France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 34 France: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 35 France: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 36 Germany: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 37 Germany: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 38 Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 39 Germany: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 40 Germany: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 41 Italy: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 42 Italy: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 43 Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 44 Italy: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 45 Italy: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 46 Spain: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 47 Spain: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 48 Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 49 Spain: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 50 Spain: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 51 Netherlands: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 52 Netherlands: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 53 Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 54 Netherlands: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 55 Netherlands: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 56 Russia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 57 Russia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 58 Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 59 Russia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 60 Russia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 61 Rest of Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 62 Rest of Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 63 Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 64 Rest of Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 65 Rest of Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 66 Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 67 Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 68 Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 69 Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 70 Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 71 China: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 72 China: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 73 China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 74 China: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 75 China: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 76 India: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 77 India: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 78 India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 79 India: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 80 India: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 81 Malaysia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 82 Malaysia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 83 Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 84 Malaysia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 85 Malaysia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 86 Japan: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 87 Japan: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 88 Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 89 Japan: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 90 Japan: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 91 Indonesia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 92 Indonesia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 93 Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 94 Indonesia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 95 Indonesia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 96 South Korea: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 97 South Korea: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 98 South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 99 South Korea: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 100 South Korea: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 101 Australia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 102 Australia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 103 Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 104 Australia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 105 Australia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 106 Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 107 Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 108 Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 109 Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 110 Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 111 Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 112 Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 113 Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 114 Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 115 Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 116 Saudi Arabia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 117 Saudi Arabia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 118 Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 119 Saudi Arabia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 120 Saudi Arabia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 121 UAE: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 122 UAE: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 123 UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 124 UAE: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 125 UAE: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 126 Israel: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 127 Israel: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 128 Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 129 Israel: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 130 Israel: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 131 South Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 132 South Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 133 South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 134 South Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 135 South Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 136 Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 137 Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 138 Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 139 Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 140 Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 141 Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 142 Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 143 Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 144 Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 145 Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 146 Mexico: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 147 Mexico: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 148 Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 149 Mexico: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 150 Mexico: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 151 Brazil: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 152 Brazil: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 153 Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 154 Brazil: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 155 Brazil: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 156 Argentina: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 157 Argentina: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 158 Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 159 Argentina: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 160 Argentina: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • Table 161 Rest of Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  • Table 162 Rest of Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  • Table 163 Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • Table 164 Rest of Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 165 Rest of Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global GLP-1 Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market By Type of Molecule
  • Figure 7. Global GLP-1 Market, By Type of Molecule, 2024 & 2034 (USD Billion)
  • Figure 8. Market By Active Compound Used
  • Figure 9. Global GLP-1 Market, By Active Compound Used, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Type of GLP-1 Agonist Drugs
  • Figure 11. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2024 & 2034 (USD Billion)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global GLP-1 Market, by Route of Administration, 2024 & 2034 (USD Billion)
  • Figure 14. Market by Target Indication
  • Figure 15. Global GLP-1 Market, by Target Indication, 2024 & 2034 (USD Billion)
目次
Product Code: PM5759

The GLP-1 Market market size is expected to reach USD 133.92 billion by 2034, according to a new study by Polaris Market Research. The report "GLP-1 Market Share, Size, Trends, Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a major role in glucose metabolism by allowing insulin release and incorporating glucagon secretion. Therapeutically, GLP-1 receptor agonists are used to treat type 2 diabetes and support weight management. The growing integration of these therapies into broader chronic disease management frameworks extends their relevance beyond type 2 diabetes to conditions such as obesity and cardiovascular risk. GLP-1 receptor agonists are being adopted as multi-targeted agents that align with evolving treatment guidelines as their clinical benefits become more widely recognized. This expanded utility is promoting greater interest among healthcare providers and patients seeking holistic, outcome-driven care solutions.

The continuous innovation led by pharmaceutical companies aims to improve drug delivery, convenience, and patient compliance. Companies are increasingly investing in next-generation formulations and combination therapies that improve metabolic outcomes with fewer side effects and lower dosing frequency. Alongside this, a growing focus on individualized treatment protocols is encouraging the development of precision-based GLP-1 therapies tailored to patient profiles. These advancements collectively point to a shift in the market toward more personalized and long-term disease control strategies.

GLP-1 Market Report Highlights

In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2024, for their extended dosing intervals, better patient compliance, and consistent clinical outcomes.

Based on route of administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period, driven by increasing preference for needle-free, convenient treatment alternatives.

In 2024, North America accounted for the largest revenue share, supported by high diabetes/obesity rates, cutting-edge healthcare systems, and rapid uptake of innovative therapies.

Asia Pacific is poised for the highest growth, fueled by surging lifestyle-related metabolic disorders and expanding healthcare accessibility.

A few global key market players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Polaris Market Research has segmented the market report on the basis of route of administration, type of molecule, active compound used, type of GLP-1 agonist drug, target indication, and region:

By Type of Molecule Outlook (Revenue, USD Billion, 2020-2034)

Biologics

Small Molecules

By Active Compound Used Outlook (Revenue, USD Billion, 2020-2034)

Dulaglutide

Liraglutide

Orforglipron

Retatrutide

Semaglutide

Survodutide

Tirzepatide

Other Active Compounds

By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 2020-2034)

Long-acting GLP-1 Agonist

Short-acting GLP-1 Agonist

By Route of Administration Outlook (Revenue, USD Billion, 2020-2034)

Oral

Parenteral

By Target Indication Outlook (Revenue, USD Billion, 2020-2034)

Alzheimer's Disease

Non-Alcoholic Steatohepatitis

Obesity

Sleep Apnea

Type 2 Diabetes

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global GLP-1 Market Insights

  • 4.1. GLP-1 Market - Material Snapshot
  • 4.2. GLP-1 Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of type 2 diabetes globally
      • 4.2.1.2. Increasing rates of obesity and related metabolic disorders
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of GLP-1 drugs and affordability challenges
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. GLP-1 Market Material Trends
  • 4.6. Value Chain Analysis

5. Global GLP-1 Market, by Type of Molecule

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global GLP-1 Market, by Type of Molecule, 2020-2034 (USD Billion)
  • 5.3. Biologics
    • 5.3.1. Global GLP-1 Market, by Biologics, by Region, 2020-2034 (USD Billion)
  • 5.4. Small Molecules
    • 5.4.1. Global GLP-1 Market, by Small Molecules, by Region, 2020-2034 (USD Billion)

6. Global GLP-1 Market, by Active Compound Used

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global GLP-1 Market, by Active Compound Used, 2020-2034 (USD Billion)
  • 6.3. Dulaglutide
    • 6.3.1. Global GLP-1 Market, by Dulaglutide, by Region, 2020-2034 (USD Billion)
  • 6.4. Liraglutide
    • 6.4.1. Global GLP-1 Market, by Liraglutide, by Region, 2020-2034 (USD Billion)
  • 6.5. Orforglipron
    • 6.5.1. Global GLP-1 Market, by Orforglipron, by Region, 2020-2034 (USD Billion)
  • 6.6. Retatrutide
    • 6.6.1. Global GLP-1 Market, by Retatrutide, by Region, 2020-2034 (USD Billion)
  • 6.7. Semaglutide
    • 6.7.1. Global GLP-1 Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
  • 6.8. Survodutide
    • 6.8.1. Global GLP-1 Market, by Survodutide, by Region, 2020-2034 (USD Billion)
  • 6.9. Tirzepatide
    • 6.9.1. Global GLP-1 Market, by Tirzepatide, by Region, 2020-2034 (USD Billion)
  • 6.10. Other Active Compounds
    • 6.10.1. Global GLP-1 Market, by Other Active Compounds, by Region, 2020-2034 (USD Billion)

7. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  • 7.3. Long-acting GLP-1 Agonist
    • 7.3.1. Global GLP-1 Market, by Long-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)
  • 7.4. Short-acting GLP-1 Agonist
    • 7.4.1. Global GLP-1 Market, by Short-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)

8. Global GLP-1 Market, by Route of Administration

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.3. Oral
    • 8.3.1. Global GLP-1 Market, by Oral, by Region, 2020-2034 (USD Billion)
  • 8.4. Parenteral
    • 8.4.1. Global GLP-1 Market, by Parenteral, by Region, 2020-2034 (USD Billion)

9. Global GLP-1 Market, by Target Indication

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 9.3. ALZHEIMER'S DISEASE
    • 9.3.1. Global GLP-1 Market, by ALZHEIMER'S DISEASE, 2020-2034 (USD Billion)
  • 9.4. Non-Alcoholic Steatohepatitis
    • 9.4.1. Global GLP-1 Market, by Non-Alcoholic Steatohepatitis, 2020-2034 (USD Billion)
  • 9.5. Obesity
    • 9.5.1. Global GLP-1 Market, by Obesity, 2020-2034 (USD Billion)
  • 9.6. Sleep Apnea
    • 9.6.1. Global GLP-1 Market, by Sleep Apnea, 2020-2034 (USD Billion)
  • 9.7. Type 2 Diabetes
    • 9.7.1. Global GLP-1 Market, by Type 2 Diabetes, 2020-2034 (USD Billion)

10. Global GLP-1 Market, by Geography

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. GLP-1 Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 10.3. GLP-1 Market - North America
    • 10.3.1. North America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.3.2. North America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.3.3. North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.3.4. North America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.3.5. North America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.3.6. GLP-1 Market - US
      • 10.3.6.1. US: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.3.6.2. US: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.3.6.3. US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.3.6.4. US: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.3.6.5. US: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.3.7. GLP-1 Market - Canada
      • 10.3.7.1. Canada: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.3.7.2. Canada: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.3.7.3. Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.3.7.4. Canada: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.3.7.5. Canada: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.4. GLP-1 Market - Europe
    • 10.4.1. Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.4.2. Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.4.3. Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.4.4. Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.4.5. Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.6. GLP-1 Market - UK
      • 10.4.6.1. UK: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.6.2. UK: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.6.3. UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.6.4. UK: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.6.5. UK: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.7. GLP-1 Market - France
      • 10.4.7.1. France: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.7.2. France: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.7.3. France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.7.4. France: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.7.5. France: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.8. GLP-1 Market - Germany
      • 10.4.8.1. Germany: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.8.2. Germany: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.8.3. Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.8.4. Germany: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.8.5. Germany: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.9. GLP-1 Market - Italy
      • 10.4.9.1. Italy: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.9.2. Italy: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.9.3. Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.9.4. Italy: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.9.5. Italy: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.10. GLP-1 Market - Spain
      • 10.4.10.1. Spain: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.10.2. Spain: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.10.3. Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.10.4. Spain: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.10.5. Spain: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.11. GLP-1 Market - Netherlands
      • 10.4.11.1. Netherlands: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.11.2. Netherlands: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.11.3. Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.11.4. Netherlands: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.11.5. Netherlands: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.12. GLP-1 Market - Russia
      • 10.4.12.1. Russia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.12.2. Russia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.12.3. Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.12.4. Russia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.12.5. Russia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.4.13. GLP-1 Market - Rest of Europe
      • 10.4.13.1. Rest of Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.4.13.2. Rest of Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.4.13.3. Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.4.13.4. Rest of Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.4.13.5. Rest of Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.5. GLP-1 Market - Asia Pacific
    • 10.5.1. Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.5.2. Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.5.3. Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.5.4. Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.5.5. Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.6. GLP-1 Market - China
      • 10.5.6.1. China: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.6.2. China: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.6.3. China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.6.4. China: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.6.5. China: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.7. GLP-1 Market - India
      • 10.5.7.1. India: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.7.2. India: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.7.3. India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.7.4. India: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.7.5. India: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.8. GLP-1 Market - Malaysia
      • 10.5.8.1. Malaysia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.8.2. Malaysia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.8.3. Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.8.4. Malaysia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.8.5. Malaysia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.9. GLP-1 Market - Japan
      • 10.5.9.1. Japan: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.9.2. Japan: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.9.3. Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.9.4. Japan: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.9.5. Japan: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.10. GLP-1 Market - Indonesia
      • 10.5.10.1. Indonesia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.10.2. Indonesia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.10.3. Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.10.4. Indonesia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.10.5. Indonesia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.11. GLP-1 Market - South Korea
      • 10.5.11.1. South Korea: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.11.2. South Korea: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.11.3. South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.11.4. South Korea: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.11.5. South Korea: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.12. GLP-1 Market - Australia
      • 10.5.12.1. Australia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.12.2. Australia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.12.3. Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.12.4. Australia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.12.5. Australia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.5.13. GLP-1 Market - Rest of Asia Pacific
      • 10.5.13.1. Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.5.13.2. Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.5.13.3. Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.5.13.4. Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.5.13.5. Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.6. GLP-1 Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.6.2. Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.6.3. Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.6.4. Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.6.5. Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.6. GLP-1 Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.6.2. Saudi Arabia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.6.3. Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.6.4. Saudi Arabia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.6.5. Saudi Arabia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.7. GLP-1 Market - UAE
      • 10.6.7.1. UAE: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.7.2. UAE: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.7.3. UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.7.4. UAE: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.7.5. UAE: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.8. GLP-1 Market - Israel
      • 10.6.8.1. Israel: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.8.2. Israel: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.8.3. Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.8.4. Israel: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.8.5. Israel: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.9. GLP-1 Market - South Africa
      • 10.6.9.1. South Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.9.2. South Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.9.3. South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.9.4. South Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.9.5. South Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.6.10. GLP-1 Market - Rest of Middle East & Africa
      • 10.6.10.1. Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.6.10.2. Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.6.10.3. Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.6.10.4. Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.6.10.5. Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
  • 10.7. GLP-1 Market - Latin America
    • 10.7.1. Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
    • 10.7.2. Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
    • 10.7.3. Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
    • 10.7.4. Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
    • 10.7.5. Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.6. GLP-1 Market - Mexico
      • 10.7.6.1. Mexico: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.6.2. Mexico: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.6.3. Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.6.4. Mexico: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.6.5. Mexico: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.7. GLP-1 Market - Brazil
      • 10.7.7.1. Brazil: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.7.2. Brazil: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.7.3. Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.7.4. Brazil: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.7.5. Brazil: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.8. GLP-1 Market - Argentina
      • 10.7.8.1. Argentina: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.8.2. Argentina: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.8.3. Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.8.4. Argentina: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.8.5. Argentina: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
    • 10.7.9. GLP-1 Market - Rest of Latin America
      • 10.7.9.1. Rest of Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
      • 10.7.9.2. Rest of Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
      • 10.7.9.3. Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
      • 10.7.9.4. Rest of Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
      • 10.7.9.5. Rest of Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. AstraZeneca
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Boehringer Ingelheim
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. D&D Pharmatech
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. Eli Lilly
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Hanmi Pharmaceutical
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Novo Nordisk
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. Pfizer
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Roche
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. Sanofi
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
  • 12.10. Tonghua Dongbao Pharmaceutical
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Benchmarking
    • 12.10.4. Recent Development